Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,607

Participants

Timeline

Start Date

December 13, 2017

Primary Completion Date

April 8, 2019

Study Completion Date

April 8, 2019

Conditions
Hepatitis B Vaccines
Interventions
BIOLOGICAL

Hepatitis B Vaccination

Prophylactic Hepatitis B Vaccination

Trial Locations (28)

30281

Clinical Research Atlanta, Atlanta

32720

Avail Clinical Research, DeLand

33135

Suncoast Research Group, Miami

35216

Accel Research Sites, Birmingham

44122

Rapid Medical Research, Cleveland

73112

Lynn Health Science Institute, Oklahoma City

83642

Advanced Clinical Research, Boise

84088

Advanced Clinical Research, Salt Lake City

89104

Clinical Research Center of Nevada, Las Vegas

92801

Anaheim Clinical Trials, Anaheim

Unknown

Universitair Ziekenhuis Gent, Ghent

BC Children's Hospital Research Institute, Vancouver

University of Manitoba, Winnipeg

Canadian Center for Vaccinology, Halifax

Ottawa Hospital, Ottawa

McGill University Health Centre, Montreal

CHU de Québec Université Laval, Québec

Espoo Vaccine Research Clinic, Espoo

Helsinki South Vaccine Research Clinic, Helsinki

Järvenpää Vaccine Research Clinic, Järvenpää

Kokkola Vaccine Research Clinic, Kokkola

Oulu Vaccine Research Clinic, Oulu

Pori Vaccine Research Clinic, Pori

Seinäjoki Vaccine Research Clinic, Seinäjoki

Tampere Vaccine Research Clinic, Tampere

University of Tampere, Tampere

Turku Vaccine Research Clinic, Turku

P3A 1W8

Medicore Research Inc, Greater Sudbury

All Listed Sponsors
lead

VBI Vaccines Inc.

INDUSTRY

NCT03393754 - Immunogenicity and Safety of Sci-B-Vac® to Engerix-B® in Adults | Biotech Hunter | Biotech Hunter